NVCR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 863 -- higher than 96.44% of US-listed equities with positive expected earnings growth.
Price to trailing twelve month operating cash flow for NVCR is currently 228.03, higher than 99.03% of US stocks with positive operating cash flow.
With a price/sales ratio of 17.28, NovoCure Ltd has a higher such ratio than 94.29% of stocks in our set.
If you're looking for stocks that are quantitatively similar to NovoCure Ltd, a group of peers worth examining would be FIVN, FLGT, FEDU, BMRN, and TRUP.
NovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for NovoCure Ltd with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that NovoCure Ltd ranked in the 97th percentile in terms of potential gain offered. Our DCF analysis implies the stock could yield a return of 15218.33% if fairly valued; such returns are always unlikely, though, so further investigation is likely warranted. In terms of the factors that were most noteworthy in this DCF analysis for NVCR, they are:
The company has produced more trailing twelve month cash flow than merely 23.72% of its sector Healthcare.
The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 8.06% of the free cash flow producing stocks we're observing.
NovoCure Ltd's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.12. This coverage rate is greater than that of merely 15.87% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVCR, try VRTX, QHC, ASRT, THC, and RDY.